Literature DB >> 32675574

Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies.

Kshitij Wagh1, Beatrice H Hahn2, Bette Korber1,3.   

Abstract

PURPOSE OF REVIEW: The surface of the HIV-1 Env glycoprotein, the target of neutralizing antibodies, is extensively covered by N-linked glycans that create a glycan shield. Broadly neutralizing antibodies (bNAbs), the primary targets of HIV-1 vaccine design, have to negotiate this glycan shield. Here, we review the barriers and opportunities that the HIV-1 glycan shield presents for vaccine induction of bNAbs. RECENT
FINDINGS: Glycan shields can impact the nature of the antibody response and influence the development of neutralization breadth in HIV-1 infections. The architecture of the glycan shield arising from glycan interactions and dynamics have been modeled, and its fine structure, that is, the site-wise glycan heterogeneity, has been determined for some isolates. Although the extent of glycan shielding is conserved, the precise number, location and processing of glycans, however, is strain-dependent. New insights continue to reveal how such differences can impact bNAb activity and development. Novel approaches have exploited the glycan shield for designing immunogens that bind the germline precursors of bNAbs, a critical roadblock for vaccine-induction of bNAbs.
SUMMARY: The HIV-1 glycan shield can significantly impact the induction and maturation of bNAbs, and a better understanding of how to manipulate it will improve immunogen design.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32675574      PMCID: PMC7877895          DOI: 10.1097/COH.0000000000000639

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.061


  58 in total

1.  Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.

Authors:  Feng Gao; Mattia Bonsignori; Hua-Xin Liao; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Fangping Cai; Kwan-Ki Hwang; Hongshuo Song; Tongqing Zhou; Rebecca M Lynch; S Munir Alam; M Anthony Moody; Guido Ferrari; Mark Berrong; Garnett Kelsoe; George M Shaw; Beatrice H Hahn; David C Montefiori; Gift Kamanga; Myron S Cohen; Peter Hraber; Peter D Kwong; Bette T Korber; John R Mascola; Thomas B Kepler; Barton F Haynes
Journal:  Cell       Date:  2014-07-24       Impact factor: 41.582

2.  Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.

Authors:  Tongqing Zhou; Nicole A Doria-Rose; Cheng Cheng; Guillaume B E Stewart-Jones; Gwo-Yu Chuang; Michael Chambers; Aliaksandr Druz; Hui Geng; Krisha McKee; Young Do Kwon; Sijy O'Dell; Mallika Sastry; Stephen D Schmidt; Kai Xu; Lei Chen; Rita E Chen; Mark K Louder; Marie Pancera; Timothy G Wanninger; Baoshan Zhang; Anqi Zheng; S Katie Farney; Kathryn E Foulds; Ivelin S Georgiev; M Gordon Joyce; Thomas Lemmin; Sandeep Narpala; Reda Rawi; Cinque Soto; John-Paul Todd; Chen-Hsiang Shen; Yaroslav Tsybovsky; Yongping Yang; Peng Zhao; Barton F Haynes; Leonidas Stamatatos; Michael Tiemeyer; Lance Wells; Diana G Scorpio; Lawrence Shapiro; Adrian B McDermott; John R Mascola; Peter D Kwong
Journal:  Cell Rep       Date:  2017-04-25       Impact factor: 9.423

3.  Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir.

Authors:  Wen-Han Yu; David Su; Julia Torabi; Christine M Fennessey; Andrea Shiakolas; Rebecca Lynch; Tae-Wook Chun; Nicole Doria-Rose; Galit Alter; Michael S Seaman; Brandon F Keele; Douglas A Lauffenburger; Boris Julg
Journal:  JCI Insight       Date:  2019-09-05

Review 4.  Germline-targeting immunogens.

Authors:  Leonidas Stamatatos; Marie Pancera; Andrew T McGuire
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

5.  Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.

Authors:  Jianhui Tian; Cesar A López; Cynthia A Derdeyn; Morris S Jones; Abraham Pinter; Bette Korber; S Gnanakaran
Journal:  PLoS Comput Biol       Date:  2016-10-07       Impact factor: 4.475

6.  Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.

Authors:  Daniel W Kulp; Jon M Steichen; Matthias Pauthner; Xiaozhen Hu; Torben Schiffner; Alessia Liguori; Christopher A Cottrell; Colin Havenar-Daughton; Gabriel Ozorowski; Erik Georgeson; Oleksandr Kalyuzhniy; Jordan R Willis; Michael Kubitz; Yumiko Adachi; Samantha M Reiss; Mia Shin; Natalia de Val; Andrew B Ward; Shane Crotty; Dennis R Burton; William R Schief
Journal:  Nat Commun       Date:  2017-11-21       Impact factor: 14.919

7.  Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.

Authors:  Max Medina-Ramírez; Fernando Garces; Amelia Escolano; Patrick Skog; Steven W de Taeye; Ivan Del Moral-Sanchez; Andrew T McGuire; Anila Yasmeen; Anna-Janina Behrens; Gabriel Ozorowski; Tom L G M van den Kerkhof; Natalia T Freund; Pia Dosenovic; Yuanzi Hua; Alexander D Gitlin; Albert Cupo; Patricia van der Woude; Michael Golabek; Kwinten Sliepen; Tanya Blane; Neeltje Kootstra; Mariëlle J van Breemen; Laura K Pritchard; Robyn L Stanfield; Max Crispin; Andrew B Ward; Leonidas Stamatatos; Per Johan Klasse; John P Moore; David Nemazee; Michel C Nussenzweig; Ian A Wilson; Rogier W Sanders
Journal:  J Exp Med       Date:  2017-08-28       Impact factor: 14.307

8.  Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.

Authors:  Weston B Struwe; Elena Chertova; Joel D Allen; Gemma E Seabright; Yasunori Watanabe; David J Harvey; Max Medina-Ramirez; James D Roser; Rodman Smith; David Westcott; Brandon F Keele; Julian W Bess; Rogier W Sanders; Jeffrey D Lifson; John P Moore; Max Crispin
Journal:  Cell Rep       Date:  2018-08-21       Impact factor: 9.423

9.  Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.

Authors:  Celia C LaBranche; Rory Henderson; Allen Hsu; Shay Behrens; Xuejun Chen; Tongqing Zhou; Kevin Wiehe; Kevin O Saunders; S Munir Alam; Mattia Bonsignori; Mario J Borgnia; Quentin J Sattentau; Amanda Eaton; Kelli Greene; Hongmei Gao; Hua-Xin Liao; Wilton B Williams; James Peacock; Haili Tang; Lautaro G Perez; Robert J Edwards; Thomas B Kepler; Bette T Korber; Peter D Kwong; John R Mascola; Priyamvada Acharya; Barton F Haynes; David C Montefiori
Journal:  PLoS Pathog       Date:  2019-09-17       Impact factor: 6.823

10.  Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail.

Authors:  Srirupa Chakraborty; Zachary T Berndsen; Nicolas W Hengartner; Bette T Korber; Andrew B Ward; S Gnanakaran
Journal:  iScience       Date:  2020-11-20
View more
  8 in total

1.  SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.

Authors:  Xiaoying Shen; Haili Tang; Charlene McDanal; Kshitij Wagh; Will Fischer; James Theiler; Hyejin Yoon; Dapeng Li; Barton F Haynes; Kevin O Sanders; Sandrasegaram Gnanakaran; Nick Hengartner; Rolando Pajon; Gale Smith; Filip Dubovsky; Gregory M Glenn; Bette Korber; David C Montefiori
Journal:  bioRxiv       Date:  2021-01-29

2.  Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.

Authors:  Tal Noy-Porat; Adva Mechaly; Yinon Levy; Efi Makdasi; Ron Alcalay; David Gur; Moshe Aftalion; Reut Falach; Shani Leviatan Ben-Arye; Shirley Lazar; Ayelet Zauberman; Eyal Epstein; Theodor Chitlaru; Shay Weiss; Hagit Achdout; Jonathan D Edgeworth; Raghavendra Kikkeri; Hai Yu; Xi Chen; Shmuel Yitzhaki; Shmuel C Shapira; Vered Padler-Karavani; Ohad Mazor; Ronit Rosenfeld
Journal:  iScience       Date:  2021-04-26

3.  SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.

Authors:  Xiaoying Shen; Haili Tang; Charlene McDanal; Kshitij Wagh; William Fischer; James Theiler; Hyejin Yoon; Dapeng Li; Barton F Haynes; Kevin O Sanders; Sandrasegaram Gnanakaran; Nick Hengartner; Rolando Pajon; Gale Smith; Gregory M Glenn; Bette Korber; David C Montefiori
Journal:  Cell Host Microbe       Date:  2021-03-05       Impact factor: 31.316

4.  The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.

Authors:  Anna Schorcht; Christopher A Cottrell; Pavel Pugach; Rajesh P Ringe; Alvin X Han; Joel D Allen; Tom L G M van den Kerkhof; Gemma E Seabright; Edith E Schermer; Thomas J Ketas; Judith A Burger; Jelle van Schooten; Celia C LaBranche; Gabriel Ozorowski; Natalia de Val; Daniel L V Bader; Hanneke Schuitemaker; Colin A Russell; David C Montefiori; Marit J van Gils; Max Crispin; P J Klasse; Andrew B Ward; John P Moore; Rogier W Sanders
Journal:  J Virol       Date:  2021-10-20       Impact factor: 5.103

5.  Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces.

Authors:  Myungjin Lee; Anita Changela; Jason Gorman; Reda Rawi; Tatsiana Bylund; Cara W Chao; Bob C Lin; Mark K Louder; Adam S Olia; Baoshan Zhang; Nicole A Doria-Rose; Susan Zolla-Pazner; Lawrence Shapiro; Gwo-Yu Chuang; Peter D Kwong
Journal:  Nat Commun       Date:  2021-11-09       Impact factor: 14.919

6.  Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time.

Authors:  Lijie Wang; Shujia Liang; Jianhua Huang; Yibo Ding; Lin He; Yanling Hao; Li Ren; Meiling Zhu; Yi Feng; Abdur Rashid; Yue Liu; Shibo Jiang; Kunxue Hong; Liying Ma
Journal:  Front Cell Infect Microbiol       Date:  2022-03-17       Impact factor: 5.293

Review 7.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

Review 8.  HIV vaccinology: 2021 update.

Authors:  Jeong Hyun Lee; Shane Crotty
Journal:  Semin Immunol       Date:  2021-07-14       Impact factor: 10.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.